刘亮胜

【摘要】 目的：探究新生儿肺炎采用重组人干扰素α1b联合盐酸氨溴索雾化吸入治疗的临床效果。方法：择取福建省汀州医院收治的62例新生儿肺炎患儿，入组时间为2022年6月—2023年6月，通过随机数字表法分为研究组（n=31）、对照组（n=31）。对照组患儿采用盐酸氨溴索雾化吸入治疗，研究组患儿采用重组人干扰素α1b联合盐酸氨溴索雾化吸入治疗，比较两组临床总有效率、临床症状消失时间、炎症因子水平、血气指标、不良反应发生率。结果：研究组患儿临床总有效率高于对照组，差异有统计学意义（P<0.05）；研究组患儿临床症状消失时间均早于对照组，差异均有统计学意义（P<0.05）；治疗后研究组患儿炎症因子水平均低于对照组，差异均有统计学意义（P<0.05）；治疗后研究组患儿动脉血氧分压（PaO2）、氧合指数均高于对照组，动脉血二氧化碳分压（PaCO2）低于对照组，差异均有统计学意义（P<0.05）；两组患儿不良反应发生率对比，差异无统计学意义（P>0.05）。结论：新生儿肺炎采用重组人干扰素α1b联合盐酸氨溴索雾化吸入治疗，效果显著，可缩短临床症状消失时间，缓解炎症反应，改善血气指标，用药后无严重不良反应。

【关键词】 重组人干扰素α1b 盐酸氨溴索 新生儿肺炎

Observation on the Effect of Recombinant Human Interferon α1b Combined with Ambroxol Hydrochloride Aerosol Inhalation in the Treatment of Neonatal Pneumonia/LIU Liangsheng. //Medical Innovation of China， 2024， 21（14）： 0-065

[Abstract] Objective： To explore the clinical effect of Recombinant Human Interferon α1b combined with Ambroxol Hydrochloride atomized inhalation for neonatal pneumonia. Method： A total of 62 children with neonatal pneumonia admitted to Fujian Tingzhou Hospital were enrolled from June 2022 to June 2023 and divided into study group （n=31） and control group （n=31） by random number table method. The control group was treated with Ambroxol Hydrochloride aerosol inhalation， and the study group was treated with Recombinant Human Interferon α1b combined with Ambroxol Hydrochloride aerosol inhalation. The total clinical effective rate， duration of disappearance of clinical symptoms， level of inflammatory factors， blood gas index and incidence of adverse reactions were compared between the two groups. Result： The total clinical effective rate of the study group was higher than that of the control group， the difference was statistically significant （P<0.05）. The disappearance time of clinical symptoms in the study group were earlier than those in the control group， the differences were statistically significant （P<0.05）. After treatment， the levels of inflammatory factors in the study group were lower than those in the control group， the differences were statistically significant （P<0.05）. After treatment， the partial oxygen pressure （PaO2） and oxygenation index in the study group were higher than those in the control group， and the partial carbon dioxide pressure （PaCO2） was lower than that in the control group， the differences were statistically significant （P<0.05）. There was no significant difference in the incidence of adverse reactions between the two groups （P>0.05）. Conclusion： Recombinant Human Interferon α1b combined with Ambroxol Hydrochloride atomized inhalation in the treatment of neonatal pneumonia has a remarkable effect， which can shorten the time of clinical symptoms to disappear， relieve inflammation， improve blood gas indexes， and no serious adverse reactions after medication.

[Key words] Recombinant Human Interferon α1b Ambroxol Hydrochloride Neonatal pneumonia

First-author's address： Department of Pediatrics， Fujian Tingzhou Hospital， Changting 366300， China

doi：10.3969/j.issn.1674-4985.2024.14.015

新生儿肺炎主要指新生儿在宫内发育或分娩过程中、出生后吸入羊水、胎粪等异物引发的肺部炎性病变，出生前后感染病毒、细菌等病原体也可引发新生儿肺炎，患儿主要临床症状为气促、咳嗽、肺部啰音、发热等，如未能及时治疗可导致患儿合并呼吸衰竭或感染性休克，甚至危及生命安全[1]。临床多采用药物对症支持治疗新生儿肺炎，盐酸氨溴索可稀释痰液，促进排痰，缓解呼吸困难等症状。重组人干扰素α1b具有抗病毒作用，可改善患儿机体免疫力[2]。本研究抽取福建省汀州医院收治的62例新生儿肺炎患儿，探析重组人干扰素α1b联合盐酸氨溴索治疗的临床效果。……